ArticleTransplantation direct2026
Reduction in Red Blood Cell Lysis by Polymer Intervention During Rodent Liver Normothermic Machine Perfusion.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Normothermic machine perfusion (NMP) has emerged as a promising strategy to improve the preservation and utilization of donor livers, particularly from extended criteria donors and those donated after circulatory death. Despite its advantages, hemolysis remains a major challenge, leading to free hemoglobin release, oxidative stress, and endothelial injury, ultimately affecting graft viability. This study evaluated the use of poloxamer 188 (P188) and Ficoll PM70 as membrane-stabilizing agents to mitigate hemolysis in rodent liver NMP models. We assessed their effects on red blood cell (RBC) stability and grafts during machine perfusion in both a model of donation after brain death and a model of warm ischemia injury. Methods: Rat livers were subjected to NMP with RBC-based perfusates containing P188 and/or Ficoll PM70, or an untreated control. Hemolysis was measured using a NanoDrop spectrophotometer to quantify the free hemoglobin concentration. Hemodynamic stability, liver injury markers, and histological analysis were analyzed to determine the overall graft viability. Results: Treatment with P188 or Ficoll PM70 significantly reduced circulating free hemoglobin in donation after brain death livers, minimizing hemolysis. Similarly, the combination of P188 and Ficoll PM70 significantly reduced hemolysis in warm ischemia livers and showed preserved liver sinusoidal endothelial cells. However, the reduction in hemolysis did not result in improved parameters measured during Conclusions: The use of Poloxamer 188 and Ficoll PM70 in NMP shows promise in reducing RBC hemolysis without compromising perfusion hemodynamics. Additionally, both polymers demonstrated improved preservation of liver sinusoidal endothelial cells, as evidenced by histological analysis. However, some findings suggest that P188 may induce the release of proinflammatory cytokines in the perfusate. Overall, these findings highlight the potential of P188 and PM70 in enhancing NMP protocols for liver transplantation, though further studies are necessary to confirm their efficacy and safety before clinical translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.